Who Paid My Doc
Sanah Christopher
Richmond, VA Medical Doctor
NPI 1710232129 CMS profile 4224093
417 N 11Th St, Im: Resident Acc Clinic, Richmond, VA 23173
General payments
$80,074
Research payments
$139
Ownership & investment interest
$0
Through program year 2025, Sanah Christopher of Richmond, VA is reported in the CMS Open Payments database as having received $80,074 across 128 general payments and $139 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $46,586 | 65 | |
| 2024 | General | $13,989 | 27 | |
| 2024 | Research | $139 | 1 | |
| 2023 | General | $19,291 | 34 | |
| 2022 | General | $155 | 1 | |
| 2021 | General | $52 | 1 |
Beside peers
- Sanah Christopher
- Virginia median
- Middle half of Virginia
- National median
In program year 2025, general payments to Sanah Christopher were reported at $46,586. Among 24,845 Virginia profiles paid that year, the median was $179 and the middle half received between $56 and $613.
Show as a table
| Year | Sanah Christopher | Virginia median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $162 | $50–$582 | $163 |
| 2020 | $0 | $111 | $36–$367 | $114 |
| 2021 | $52 | $125 | $37–$450 | $132 |
| 2022 | $155 | $149 | $45–$527 | $149 |
| 2023 | $19,291 | $161 | $50–$554 | $160 |
| 2024 | $13,989 | $171 | $55–$585 | $164 |
| 2025 | $46,586 | $179 | $56–$613 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 21 drugsPart D claims
1,654
Drug cost
$673,459
Branded share of claims
35.4%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 219 | $305,608 | |
| Entresto Sacubitril/Valsartan | Brand | 103 | $154,538 | |
| Jardiance Empagliflozin | Brand | 84 | $123,852 | |
| Brilinta Ticagrelor | Brand | 72 | $65,509 | |
| Atorvastatin Calcium | Generic | 192 | $7,296 | |
| Metoprolol Succinate | Generic | 297 | $4,816 | |
| Ezetimibe | Generic | 38 | $2,508 | |
| Rosuvastatin Calcium | Generic | 43 | $1,832 | |
| Losartan Potassium | Generic | 116 | $1,341 | |
| Clopidogrel Clopidogrel Bisulfate | Brand | 60 | $1,290 |
The 10 drugs with the highest cost, of 21 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 554 Part D prescribers listed as Interventional Radiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 44 billing codesPaid by Medicare
$77,969
Medicare patients
410
Services billed
1,123
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Chronic kidney disease | 58% | |
| Ischemic heart disease | 54% | |
| Diabetes | 47% | |
| Heart failure | 36% | |
| Atrial fibrillation | 35% | |
| Arthritis | 34% | |
| Osteoporosis | 21% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
129 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.